NeoGenomics And German Breast Group Highlight Jun. 2 Presentation New Data Demonstrating Clinical Potential Of RaDaR MRD Assay In HR+/HER2- Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
NeoGenomics (NASDAQ:NEO) announced new data supporting its RaDaR assay for detecting molecular residual disease (MRD) and recurrence in high-risk HR+/HER2- breast cancer patients. The data comes from a retrospective analysis of the Phase 3 PENELOPE-B study presented at the 2023 ASCO Annual Meeting.
June 05, 2023 | 11:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeoGenomics announced new data supporting its RaDaR assay for detecting MRD in high-risk breast cancer patients, potentially increasing demand for the test.
The new data from the Phase 3 PENELOPE-B study supports the clinical potential of NeoGenomics' RaDaR assay in detecting MRD and recurrence in high-risk breast cancer patients. This could lead to increased demand for the test, positively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100